A clinical trial to study the effects of two different doses of Intravitreal Ranibizumab in patients with Aggressive Posterior Retinopathy of Prematuriy.
Not Applicable
- Conditions
- Health Condition 1: H351- Retinopathy of prematurity
- Registration Number
- CTRI/2020/07/026347
- Lead Sponsor
- Dr Rajendra Prasad Centre for Ophthalmic Science All India Institute of Medical Science New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Pre-term babies (Gestational Age < 34 weeks)
2. Birth Weight <2000gm
3. Zone I â?? Zone II Posterior APROP
4. Bilateral symmetrical disease
Exclusion Criteria
1. Advanced stage disease (stage 4/ 5 ROP)
2. Zone II anterior and Zone III disease (non-APROP)
3. Any previous intervention done (Laser/ Anti-VEGF)
4. Any other ocular abnormality
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study disease regression with two different doses of intravitreal Ranibizumab in APROP.Timepoint: Week 1,2,4,8,12
- Secondary Outcome Measures
Name Time Method eed for additional interventionTimepoint: Week 1, 2, 4, 8 and 12;To observe the extent of re-vascularisation of retina <br/ ><br> <br/ ><br>Timepoint: Compared Pre-injection (Day 0) and Post-injection week 8